Finance & Capital Markets

  1. Biotech Story Time With Tal Zaks, M.D. (Part 2) 1/5/2025

    Dr. Tal Zaks joins the Business of Biotech for the second part of "Story Time With Tal," discussing his transition from Moderna's CMO during the COVID-19 pandemic to co-founding Exsilio Therapeutics, an mRNA startup. The episode explores Exsilio's foundation, scientific focus, team recruitment, and its $82 million Series A funding led by Novartis Venture Fund and Delos Capital, with support from prominent investors like OrbiMed, CRISPR Therapeutics, and J.P. Morgan Life Sciences Private Capital.

  2. Managing Mergers With Sail's Guillaume Pfefer, Ph.D 2/15/2024

    You might be aware that Sail Biomedicines was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger was executed, how the two companies are integrating their talent, IP, and resources, and what Sail Biomedicines CEO Dr. Guillaume Pfefer and team are currently doing to take the fruits of the company’s platform into the clinic. 

  3. BoB@JPM: Peter Anastasiou, Capsida Biotherapeutics 2/9/2025

    From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, discusses his journey from big pharma to biotech and the challenges he faces on the leading edge of first-generation gene therapies.

  4. Biotech Investing At The Earliest Stages With Santé Ventures' Omar Khalil 8/19/2026

    On this week's episode of the Business of Biotech, Omar Khalil, Managing Director at Santé Ventures, describes forming and funding startups and early-stage biotech companies with a focus on clinical data and differentiation as the key value drivers.

  5. Building A Biotech Incubator And Accelerator With Swiss Rockets Founder And CEO Vladimir Cmiljanovic, Ph.D. 8/21/2025

    On this week's episode, ex-handballer Vladimir Cmiljanovic, Ph.D., Founder and CEO at Swiss Rockets, talks about co-discovering bimiralisib with his sister Natasa Cmiljanovic, Ph.D. (and COO at Swiss Rockets), losing his company to a hostile takeover, buying the company back, and building out Swiss Rockets as an incubator with manufacturing capabilities and shared scientific expertise.

  6. Biotech Angel Investing With Yaniv Sneor 5/21/2025

    On this week's Business of Biotech episode, Yaniv Sneor, founder of the Mid Atlantic Bio Angels and CEO at Native State Therapeutics, explains how life science angel investors evaluate biotech startups, and offers tips for young drug developers in search of funding. The conversation covers how to create a successful pitch, red flags for potential investors, the importance of angel investing syndicates, the sweet spots for exit timelines and funding amounts, and why it still makes sense to invest in biotech over other industry sectors.

  7. Funding Tips And Moving From R&D To Commercial With Madrigal Pharmaceuticals' Mardi Dier 11/5/2025

    On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer. 

  8. Strategic Deals With CinRx's Gavin Samuels, M.D. 3/17/2024

    Gavin Samuels, M.D., found his work as an intensive care physician boring. It wasn't until he left the hospital and entered biopharma that he found his footing. Now, he's Chief Business Officer and General Partner at CinRx Pharma, where a deep pipeline of early- to late-stage candidates keeps him on his dealmaking toes. Dr. Samuels' introspective reflections on biotech dealmaking and negotiations plants this episode firmly on the Business of Biotech podcast highlight reel.

  9. A $1B AI Bet With Foresite Labs' Vik Bajaj, Ph.D. 12/15/2024

    This past spring, Xaira Therapeutics launched with $1 billion in backing, a who's-who mashup of Silicon Valley and biopharma stars led by Marc Tessier-Lavigne in the C-suite, and a mission to develop AI-generated drugs. On this week's episode of the Business of Biotech, we're digging into the company's origin story and its place on the greater techbio landscape with one of the men bearing responsibility for Xaira's launch.

  10. BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience 1/29/2025

    From the JP Morgan Healthcare Conference in San Francisco, Dr. Stefan Scherer shares insight from 3T Bioscience's transition from clinical medicine to drug development, and his experiences in biotech leadership along the way.